Spyre Therapeutics, Inc. earns a Strong Buy on Phase 1 wins, IBD/RA pipeline catalysts, and $757M cash runway. Click for this ...

Abivax is advancing obefazimod, a first-in-class oral therapy for UC and CD, with major upcoming data catalysts. Click here ...

APEX Part A data demonstrated durable maintenance of response at 52-weeks for every 3- and 6-months dosing, respectively, including:- 75% and 85% ...

San Marcos nonprofit Wounded Warrior Homes is expanding housing and mental health services for veterans, including a brain treatment program.

Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AMLHOUSTON, ...

Dr. Ajay Nooka, director of the Myeloma program at Winship Cancer Institute of Emory University, simplifies the International Myeloma Working Group criteria for disease progressio ...

RESEDA, CA - March 20, 2026 - PRESSADVANTAGE - Moment of Clarity has released a detailed educational resource outlining ...

When Aardvark Therapeutics announced earlier this month that it was pausing a phase 3 trial of its lead metabolic candidate, ...

A dual VEGF-A and angiopoietin-2 inhibitor provided fast, durable treatment for wet age-related macular degeneration in a ...

Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR. Cue Biopharma management and KOLs will discuss CUE-401, the companys ...

With thoracic oncology in the middle of a combinatorial revolution—EGFR-targeted doublets and triplets, a maturing antibody-drug conjugate (ADC) pipeline, next-generation small cell lung cancer (SCLC) ...

AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient ...